The silencing of ERα expression in the SKOV3 ovarian cancer cell line not only inhibited estrogen-stimulated growth but also reversed the inhibitory effects of 4-hydroxytamoxifen (the active metabolite of tamoxifen) and fulvestrant, consistent with ERα mediating the effects of these anti-estrogens [37]. This evidence concerns the gene ESR1 and ovarian carcinoma.